Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.30 – $2.42
27% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $231.0M | $273.4M | $390.8M | $511.1M | $625.7M | $839.5M | $594.5M | $960.9M |
| Cost of revenue | $72.5M | $93.1M | $135.0M | $207.6M | $321.6M | $430.0M | $322.4M | $406.9M |
| Gross profit | $158.5M | $180.3M | $255.9M | $282.5M | $304.1M | $409.6M | $272.1M | $554.0M |
| Gross margin | 68.6% | 66.0% | 65.5% | 55.3% | 48.6% | 48.8% | 45.8% | 57.7% |
| R&D | $74.1M | $186.0M | $263.4M | $358.4M | $390.1M | $433.8M | $53.8M | $71.3M |
| Operating income | $22.4M | −$112.1M | −$204.5M | −$368.3M | −$436.0M | −$415.8M | $9.3M | $255.6M |
| EBITDA | $35.4M | −$92.5M | −$171.6M | −$465.8M | −$355.1M | −$248.7M | $70.0M | $329.8M |
| Net income | $21.2M | −$96.9M | −$204.9M | −$358.7M | −$226.9M | −$95.5M | $2.96B | −$533.6M |
| Net margin | 9.2% | -35.5% | -52.4% | -70.2% | -36.3% | -11.4% | 498.2% | -55.5% |
| EPS (diluted) | 0.01 | -0.05 | -0.11 | -0.18 | -0.11 | -0.05 | 1.36 | -0.25 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $810M | $0.03 | $0.03–$0.04 | 1 |
| 2027 | $949M | $0.06 | $0.05–$0.06 | 1 |
| 2028 | $1.1B | $0.08 | $0.08–$0.09 | 1 |
Forward consensus · source: Financial Modeling Prep
GENSCRIPT BIOTECH CRP ORD
No one on the platform currently holds GNNSF.
No tracked institution reports a position in GNNSF as of their last filing.
No one on the platform has traded GNNSF yet.
| $2.3B |
| — |
| LABFFLaboratorios Farmaceuticos Rovi, S.A. | $90.61 | +0.00% | $4.6B | — |
| SGFEFSiegfried Holding AG | $84.12 | +0.00% | $3.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 2.3× sales vs its 6.1× historical median P/S.
Fair value ≈ $4.27 · price $1.60 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.